Skip to main content
. 2014 May 21;9:77. doi: 10.1186/1750-1172-9-77

Table 3.

Clinical features, laboratory tests, and pancreatic morphology at diagnosis (From Ref. [54])

  Progression to CP
 Non-progression to CP
 P value
(n = 16) (n = 57)  
Clinical features
 Median (range)
  
Observation period§
 102 (37–165)
 87 (36–230)
 0.522
 Age
 66.5 (48–75)
 65 (38–84)
 0.989
 Gender (M/F)
 13/3
 43/14
 0.748
 Alcohol (+/−)
 6/10
 29/28
 0.405
 PSL (+/−)
 13/3
 50/7
 0.681
 PSL maintenance therapy (+/−)
 10/6
 41/16
 0.542
 Relapse (+/−)
 8/8
 12/45
 0.030 *
Laboratory tests
  
  
 IgG
 2140 (1166–3861)
 2227 (892–7236)
 0.509
 IgG4
 421 (146–1845)
 663 (4–2970)
 0.267
 C3
 100 (52–122)
 98 (29–218)
 0.551
 C4
 21.8 (12.4–37.7)
 21.1 (1.1–47.3)
 0.495
 sIL2-R
 726 (132–1845)
 892 (257–4695)
 0.053
 CIC
 5 (1.9–13.9)
 5.7 (1.4–40)
 0.219
Pancreatic morphology at diagnosis
  
  
Pancreatic swelling (by CT)
  
  
  
 Head (+/−)
 15/1
 41/16
 0.096
 Body (+/−)
 12/4
 36/21
 0.553
 Tail (+/−)
 10/6
 37/20
 1.000
 Level 1/Level 2Φ
 8/8
 30/27
 1.000
Ductal narrowing in MPD (by ERP)
  
  
  
 Head (+/−)
 13/3
 44/13
 1.000
  Wirsung & Santorini (+/−)
 11/5
 34/23
 0.573
 Body (+/−)
 3/13
 37/20
 0.001 *
 Tail (+/−)
 12/4
 42/15
 1.000
 Level 1/Level 2Ψ
 6/10
 17/40
 0.558
Ductal dilatation in MPD (+/−) 9/7 7/50 0.001*

§Period from AIP diagnosis to the most recent observation (months).

ΦSwelling was classified as level 1 (diffuse swelling) or level 2 (focal/segmental swelling) as defined by the International Consensus Diagnostic Criteria for Autoimmune Pancreatitis.

ΨPancreatic duct narrowing was classified as level 1 (long [segmental/diffuse] or multiple strictures) or level 2 (focal narrowing) as defined by the International Consensus Diagnostic Criteria for Autoimmune Pancreatitis.

*P < 0.05.

CP: chronic pancreatitis, PSL: prednisolone, sIL2-R: soluble interleukin 2 receptor,

CIC: circulating immune complex, MPD: main pancreatic duct.